Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

106.20
+2.922.83%
Post-market: 106.200.00000.00%16:15 EDT
Volume:732.75K
Turnover:78.54M
Market Cap:5.94B
PE:-25.82
High:109.79
Open:106.78
Low:105.00
Close:103.28
52wk High:117.88
52wk Low:32.22
Shares:55.93M
Float Shares:55.85M
Volume Ratio:1.15
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1130
EPS(LYR):-4.2037
ROE:-26.07%
ROA:-17.69%
PB:5.07
PE(LYR):-25.26

Loading ...

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year

Reuters
·
Aug 06

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain

Reuters
·
Aug 05

Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (DNTH) and American Well (AMWL)

TIPRANKS
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Aug 05

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 05

Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics Inc Q2 Operating Expenses USD 62.243 Million

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics Inc Expected to Post a Loss of 86 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Dianthus Therapeutics Grants 87,000 Inducement Stock Options at $106.02 Per Share

Reuters
·
Aug 04

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

Movement Alert|Dianthus Therapeutics Rises 9.22% in Regular Trading, Trading at $104.14

Market Focus
·
Jul 18

Dianthus Therapeutics EVP, CFO and CBO Ryan Savitz Disposes of Common Shares Worth $3.06 Million

Reuters
·
Jul 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 06